What is 10x Genomics, Inc.'s SG&A?

10x Genomics, Inc. (TXG) reported SG&A of $66.38M in Q1 2026.

How has 10x Genomics, Inc.'s SG&A changed year-over-year?

10x Genomics, Inc.'s SG&A decreased by 26.0% year-over-year, from $89.73M to $66.38M.

What is the long-term trend for 10x Genomics, Inc.'s SG&A?

Over 4 years (2021 to 2025), 10x Genomics, Inc.'s SG&A has grown at a 5.3% compound annual growth rate (CAGR), from $257.56M to $316.13M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

10x Genomics, Inc. TXG SG&A

SG&A at other companies

TEC

Bio-TechneTECH

$109.34M-27.7%

BrukerBRKR

$242.1M+7.4%

IlluminaILMN

$272M+1.9%

Twist Bioscience CorporationTWST

$76.09M+19.5%

RevvityRVTY

$253.88M+1.7%

Bio-Rad LaboratoriesBIO

$212.4M+1.7%

Other financials

Income statement

See full

Revenue$150.8M-2.6%

Gross profit$106.2M+0.7%

Operating income-$17.0M+56.7%

Net income-$13.5M+60.8%

EPS (diluted)-$0.10+64.3%

Balance sheet

See full

Cash & equivalents$490.3M+30.0%

Total debt$81.4M+1.6%

Total equity$814.3M+15.2%

Total assets$1.0B+12.4%

Cash flow

See full

Operating cash flow$26.1M-24.0%

CapEx$1.6M-15.6%

Free cash flow$24.5M-24.4%

Valuation

See full

Market cap$4.41B+154%

Profitability

See full

Gross margin69.6%+1.2pp

Operating margin-6.1%-2.7pp

Net margin-3.5%-1.6pp

FCF margin19.1%—

Returns & leverage

See full

Return on equity-3%-1.4pp

Debt / equity0.1×0.0×

Current ratio5.9×+0.5×

Where this comes from

Reported directly by 10x Genomics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about 10x Genomics, Inc.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is 10x Genomics, Inc.'s SG&A?: 10x Genomics, Inc. (TXG) reported SG&A of $66.38M in Q1 2026.
How has 10x Genomics, Inc.'s SG&A changed year-over-year?: 10x Genomics, Inc.'s SG&A decreased by 26.0% year-over-year, from $89.73M to $66.38M.
What is the long-term trend for 10x Genomics, Inc.'s SG&A?: Over 4 years (2021 to 2025), 10x Genomics, Inc.'s SG&A has grown at a 5.3% compound annual growth rate (CAGR), from $257.56M to $316.13M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.